Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline's losmapimod heart drug failed to work as expected in the first part of a large clinical trial.
Subscribe to our email newsletter
The company said a review of data from a phase III trial of losmapimod for heart treatment did not indicate efficacy against the primary endpoint.
Losmapimod was being evaluated as a treatment to reduce the risk of further cardiovascular problems after heart attacks. The company said the results did not support investment in the larger part B of the study as currently designed.
The company found an efficacy signal in a sub-population of patients (n=866) classified with ST elevation myocardial infarction (STEMI).
GSK said even though not statistically significant, because of the relatively small number of events (n=59), reductions between 30% and 50% in the pre-specified endpoints of cardiovascular death, hospitalisation for heart failure, and the composite of the two were observed.
The company said it will assess the findings in the next few months to identify all options for future development.
In a separate press release, GSK said its Shingrix candidate vaccine demonstrated 90% efficacy in avoiding the disease in people more than 70 years.
The company is planning to submit it for regulatory approval in the second half of next year.